Skin toxicity of targeted cancer agents: Mechanisms and intervention

Future Oncology

Volumn 9, Issue 8, 2013, Pages 1161-1170

  Belum, Viswanath Reddy ^a   Fontanilla Patel, Hiral ^b   Lacouture, Mario E ^a   Rodeck, Ulrich ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b University Medical Centre Princeton   (United States)

Author keywords

BRAF; EGFR; immunomodulation; MEK; RAS RAF MEK MAPK; skin toxicity; targeted agent

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETANERCEPT; INTERLEUKIN 1; MENADIONE; MITOGEN ACTIVATED PROTEIN KINASE; VEMURAFENIB;

ACNE; ADAPTIVE IMMUNITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG ERUPTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HAIR DISEASE; HAIR FOLLICLE; HUMAN; INNATE IMMUNITY; KERATINOCYTE; MUCOSA INFLAMMATION; NAIL DISEASE; PAPULE; PRIORITY JOURNAL; PUSTULE; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; SKIN CARCINOMA; SKIN TOXICITY;

DRUG TOXICITY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SKIN ABNORMALITIES;

EID: 84881305973     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.62     Document Type: Review

References (82)

1. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br. J. Clin. Pharmacol. 71 (5), 684-700 (2011).
2. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur. J. Dermatol. 10 (7), 505-510 (2000).
3. Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269 (5221), 234-238 (1995).
4. Threadgill DW, Dlugosz AA, Hansen LA et al. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 269 (5221), 230-234 (1995).
5. Murillas R, Larcher F, Conti CJ, Santos M, Ullrich A, Jorcano JL. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J. 14 (21), 5216-5223 (1995).
6. Mann GB, Fowler KJ, Gabriel A, Nice EC, Williams RL, Dunn AR. Mice with a null mutation of the TGFa gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73 (2), 249-261 (1993).
7. Franzke CW, Cobzaru C, Triantafyllopoulou A et al. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. J. Exp. Med. 209 (6), 1105-1119 (2012).
8. Fowler KJ, Walker F, Alexander W et al. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc. Natl Acad. Sci. USA 92 (5), 1465-1469 (1995).
9. Mak KK, Chan SY. Epidermal growth factor as a biologic switch in hair growth cycle. J. Biol. Chem. 278 (28), 26120-26126 (2003).
10. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 6 (10), 803-812 (2006).
11. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: Pharmacogenetics and clinical syndromes. J. Allergy Clin. Immunol. 127 (3 Suppl.), S60-S66 (2011).
12. Kollmannsberger C, Schittenhelm M, Honecker F et al. A Phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 17 (6), 1007-1013 (2006).
13. Gatzemeier U, Von Pawel J, Vynnychenko I et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX Phase 3 study. Lancet Oncol. 12 (1), 30-37 (2011).
14. Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr. Opin. Oncol. 23 (4), 343-351 (2011).
15. Luu M, Boone SL, Patel J et al. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. Clin. Exp. Dermatol. 36 (7), 733-738 (2011).
16. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [see comment]. J. Clin. Oncol. 20 (21), 4292-4302 (2002).
17. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Textbook of Adverse Drug Reactions. Davies DM (Ed.). Oxford University Press, Oxford, UK, 18-45 (1991).
18. Joshi SS, Ortiz S, Witherspoon JN et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116 (16), 3916-3923 (2010).
19. Perez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10 (5), 345-356 (2005).
20. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. J. Am. Acad. Dermatol. 56 (2), 317-326 (2007).
21. Roe E, Garcia Muret MP, Marcuello E, Capdevila J, Pallares C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients. J. Am. Acad. Dermatol. 55 (3), 429-437 (2006).
22. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol. 16 (9), 1425-1433 (2005).
23. Chen AP, Setser A, Anadkat MJ et al. Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0. J. Am. Acad. Dermatol. 67 (5), 1025-1039 (2012).
24. Scope A, Agero AL, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J. Clin. Oncol. 25 (34), 5390-5396 (2007).
25. Lacouture ME, Mitchell EP, Piperdi B et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a Phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J. Clin. Oncol. 28 (8), 1351-1357 (2010).
26. Eilers RE Jr, Gandhi M, Patel JD et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J. Natl Cancer Inst. 102 (1), 47-53 (2010).
27. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br. J. Dermatol. 153 (4), 849-851 (2005).
28. Bernier J, Bonner J, Vermorken JB et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann. Oncol. 19 (1), 142-149 (2008).
29. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist 12 (5), 610-621 (2007).
30. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. 144 (6), 1169-1176 (2001).
31. Eames T, Grabein B, Kroth J, Wollenberg A. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J. Eur. Acad. Dermatol. Venereol. 24 (8), 958-960 (2010).
32. Lee MW, Seo CW, Kim SW et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm. Venereol. 84 (1), 23-26 (2004).
33. Sugita K, Kabashima K, Atarashi K, Shimauchi T, Kobayashi M, Tokura Y. Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin. Clin. Exp. Immunol. 147 (1), 176-183 (2007).
34. Auletta JJ, Alabran JL, Kim BG, Meyer CJ, Letterio JJ. The synthetic triterpenoid, CDDO-Me, modulates the proinflammatory response to in vivo lipopolysaccharide challenge. J. Interferon Cytokine Res. 30 (7), 497-508 (2010).
35. Gutowska-Owsiak D, Ogg GS. The epidermis as an adjuvant. J. Invest. Dermatol. 132 (3 Pt 2), 940-948 (2012).
36. Luger TA, Schwarz T. Evidence for an epidermal cytokine network. J. Invest. Dermatol. 95 (Suppl. 6), S100-S104 (1990).
37. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. J. Pathol. 163 (1), 303-312 (2003).
38. Pastore S, Mascia F, Mariotti F, Dattilo C, Mariani V, Girolomoni G. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J. Immunol. 174 (8), 5047-5056 (2005).
39. Saaf A, Pivarcsi A, Winge MC et al. Characterization of EGFR and ErbB2 expression in atopic dermatitis patients. Arch. Dermatol. Res. 304 (10), 773-780 (2012).
40. Mascia F, Cataisson C, Lee TC et al. EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. J. Invest. Dermatol. 130 (3), 682-693 (2010).
41. Bourke E, Cassetti A, Villa A, Fadlon E, Colotta F, Mantovani A. IL-1b scavenging by the type II IL-1 decoy receptor in human neutrophils. J. Immunol. 170 (12), 5999-6005 (2003).
42. Kasper M, Schnidar H, Neill GW et al. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol. Cell. Biol. 26 (16), 6283-6298 (2006).
43. Shoham NG, Centola M, Mansfield E et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl Acad. Sci. USA 100 (23), 13501-13506 (2003).
44. Wise CA, Gillum JD, Seidman CE et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum. Mol. Genet. 11 (8), 961-969 (2002).
45. Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr. Dermatol. 22 (3), 262-265 (2005).
46. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxf.) 44 (3), 406-408 (2005).
47. Gerber PA, Kukova G, Buhren BA, Homey B. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology 222 (2), 144-147 (2011).
48. Niyonsaba F, Ushio H, Nakano N et al. Antimicrobial peptides human b-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J. Invest. Dermatol. 127 (3), 594-604 (2007).
49. Surguladze D, Deevi D, Claros N et al. Tumor necrosis factor-a and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res. 69 (14), 5643-5647 (2009).
50. Kalliolias GD, Liossis SNC. The future of the IL-1 receptor antagonist anakinra: From rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin. Investig. Drugs 17 (3), 349-359 (2008).
51. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7 (1), e30275 (2012).
52. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J. Clin. Oncol. 23 (22), 5235-5246 (2005).
53. Perez-Soler R, Zou Y, Li T, Ling YH. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clin. Cancer Res. 17 (21), 6766-6777 (2011).
54. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (1), 11-22 (2003).
55. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417 (6892), 949-954 (2002).
56. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5 (11), 875-885 (2004).
57. Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22 (30), 4757-4759 (2003).
58. Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467 (7315), 596-599 (2010).
59. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364 (26), 2507-2516 (2011).
60. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363 (9), 809-819 (2010).
61. Chu EY, Wanat KA, Miller CJ et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J. Am. Acad. Dermatol. 67 (6), 1265-1272 (2012).
62. Zimmer L, Hillen U, Livingstone E et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J. Clin. Oncol. 30 (19), 2375-2383 (2012).
63. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, Phase 3 randomised controlled trial. Lancet 380 (9839), 358-365 (2012).
64. Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A Phase 1 dose-escalation trial. Lancet 379 (9829), 1893-1901 (2012).
65. Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, Phase 2 trial. Lancet Oncol. 13 (11), 1087-1095 (2012).
66. Williams VL, Cohen PR, Stewart DJ. Sorafenib-induced premalignant and malignant skin lesions. Int. J. Dermatol. 50 (4), 396-402 (2011).
67. Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J. Am. Acad. Dermatol. 61 (3), 522-527 (2009).
68. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin. Genit. Cancer 7 (1), 20-23 (2009).
69. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366 (3), 207-215 (2012).
70. Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: Practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br. J. Dermatol. 167 (5), 987-994 (2012).
71. Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464 (7287), 431-435 (2010).
72. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464 (7287), 427-430 (2010).
73. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 30 (3), 366-371 (2011).
74. Oberholzer PA, Kee D, Dziunycz P et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30 (3), 316-321 (2012).
75. Roring M, Herr R, Fiala GJ et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 31 (11), 2629-2647 (2012).
76. Poulikakos PI, Persaud Y, Janakiraman M et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 480 (7377), 387-390 (2011).
77. Callahan MK, Rampal R, Harding JJ et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367 (24), 2316-2321 (2012).
78. Lacouture ME, O'Reilly K, Rosen N, Solit DB. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: Cause for concern? J. Clin. Oncol. 30 (3), 329-330 (2012).
79. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367 (18), 1694-1703 (2012).
80. Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Cutaneous effects of BRAF inhibitor therapy: A case series. Ann. Oncol. 24 (2), 530-537 (2013).
81. Gysin S, Salt M, Young A, Mccormick F. Therapeutic strategies for targeting Ras proteins. Genes Cancer 2 (3), 359-372 (2011).
82. Le K, Blomain E, Rodeck U, Aplin AE. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 26 (4), 509-517 (2013).